Worth.com
“Because of this preclinical data that’s really compelling, that rapamycin is really a very robust drug in terms of extending health and lifespan, people started to take it off-label,“ says Yousin Suh, who researches reproduction and genetics at Columbia University. “Especially people who know that they have risk factors for age-related diseases such as heart disease.“
